Dynavax Technologies Corp. won't seek European approval of its experimental hepatitis B vaccine Heplisav — for now. The Berkeley company (NASDAQ: DVAX) opted to withdraw its application for approval, it said Tuesday, after European regulators said the drug's safety database is too small to rule out the risk of less-common serious adverse events. The 180 days that Europe imposes on companies to fix problems with an application isn't long enough to collect more clinical data, the company said. An…
Reported by bizjournals 2 hours ago.
↧